Symbicort 160 / 4.5 mcg 60 doses

Tradename:

Symbicort

Symbicort

Composition:

budesonide micronized 160 mcg

formoterol fumarate dihydrate 4.5 mcg

Auxiliary components:

lactose monohydrate – 730 mcg.

Properties:

Symbicort@ contains budesonide and formoterol, which have different mechanisms of action and exhibit an additive effect in reducing the frequency of exacerbations of bronchial asthma. The special properties of budesonide and formoterol make it possible to use their combination to relieve attacks / symptoms with anti-inflammatory action, or as a supportive therapy for bronchial asthma.

Indications:

bronchial asthma, in order to achieve general control of the disease, including prevention and relief of symptoms, and reduce the risk of exacerbations, also for the treatment of bronchial asthma of any severity, if it is advisable to use inhaled GCS;

COPD, as symptomatic therapy in patients with post-bronchodilatory FEVI < 70% of the expected value and with a history of exacerbations, despite regular therapy with bronchodilators.

Application mode:

The selection of the dose of the drugs that make up Symbicort@ is carried out individually and depending on the severity of the disease. This must be taken into account not only when starting treatment with combined drugs, but also when changing the maintenance dose of the drug.

Patients should be under constant medical supervision for adequate selection of the dose of Symbicort@ Turbuhaler@.

Recommended dose:

Adults over 18:

1-2 inhalations 2 r/ day, maximum 4 r/ day

Patients 12-17 years old: 1-2 inhalations 2P/day

Children over 6 years old (indicated for the use of Sumbicort at a dosage of 80 mcg) 2 inhalations 2 r/ day

Sumbicort is not recommended for children under 6 years of age.

Contraindications:

-increased sensitivity to budesonide, formoterol or inhaled lactose;

-Children under 6 years old;

lactose intolerance, lactase deficiency or glucose-galactose malabsorption).

With caution: pulmonary tuberculosis (active or inactive form), fungal, viral or bacterial respiratory infections.

Precautions:

During therapy with Symbicort@ Turbuhaler@, exacerbations and the development of serious adverse events associated with bronchial asthma may occur. Patients should continue treatment, but seek medical attention if symptoms of bronchial asthma are not controlled or if the condition worsens after starting therapy.

Side effects:

From the nervous system: often headache; anxiety, nausea, dizziness, sleep disturbances;

On the part of the cardiovascular system: often palpitations;

From the respiratory system: often candidiasis of the mucous membrane of the mouth and pharynx, cough, hoarseness, slight irritation in the throat;

Allergic reactions: rarely, hypersensitivity reactions of an immediate and delayed type (for example, urticaria, angioedema, anaphylactic reactions).

Storage method:

In a dry, dark, cool place at a temperature not exceeding 30 degrees.

Packaging:

60 doses – plastic inhalers with control of the first opening (protective film indicating the place of opening) – cardboard packs.